Development of cyclic γ-MSH analogues with selective hHMC3R agonist and hMC3R/hMC5R antagonist activities

Alexander V. Mayorov, Minying Cai, Kevin B. Chandler, Ravil R. Petrov, April R. Van Scoy, Zerui Yu, Dustin K. Tanaka, Dev Trivedi, Victor J Hruby

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


A series of cyclic lactam analogues of γ-MSH (H-Tyr 1-Val2-Met3-Gly4-His 5-Phe6-Arg7-Trp8-Asp 9-Arg10-Phe11-Gly12-OH) with a bulky hydrophobic residue in the direct proximity to the pharmacophore (Xaa-D-Phe/D-Nal(2′)-Arg-Trp) were designed and synthesized by solid-phase methods. A variety of amino acids with a broad range of hydrophobic/hydrophilic properties was introduced in position 5 to further explore their complementary role in receptor selectivity. Biological evaluation of these peptides revealed several analogues with potent hMC3R agonist and hMC3R/hMC5R antagonist activities, and good receptor selectivity. Analogue 4, c[Nle-Arg-D-Phe-Arg-Trp- Glu]-NH2, was found to be a very potent and selective hMC3R agonist (EC50 = 1.2 nM, 112% act). In addition, analogue 13, c[Nle-Val-D-Nal(2′)-Arg-Trp-Glu]-NH2, was identified as an hMC3R/hMC5R antagonist with the best selectivity against the hMC4R in this series (pA2(hMC3R) = 8.4; pA2(hMC5R) = 8.7). These results indicate the significance of steric factors in melanocortin receptor selectivity and suggest that introduction of bulky residues in the direct proximity to the melanocortin pharmacophore is an effective approach to design of novel hMC3R and hMC5R selective ligands.

Original languageEnglish (US)
Pages (from-to)1946-1952
Number of pages7
JournalJournal of Medicinal Chemistry
Issue number6
StatePublished - Mar 23 2006

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'Development of cyclic γ-MSH analogues with selective hHMC3R agonist and hMC3R/hMC5R antagonist activities'. Together they form a unique fingerprint.

Cite this